Strata Critical Medical, Inc.
NASDAQ:SRTAAirlines, Airports & Air Services
-$0.03 today
- Market cap
- $443.03M
- Beta
- 2.20
- P/E (TTM)
- 9.7
- EPS (TTM)
- $0.60
Volume 0.99M
Average 0.91M
SRTA Stock-Based Compensation
Employee pay granted in shares or options; a non-cash expense that dilutes existing shareholders.
Strata Critical Medical, Inc.NASDAQ: SRTA
Stock-Based Compensation · Q1 FY2026 · quarter ended Mar 2026
Stock-based compensation outflow grows to $0
Q1 FY2026 stock-based compensation was $0, compared with $0 a year earlier. Trailing-twelve-month stock-based compensation was $6.59M. Over 3 fiscal years it compounded at +29.2% a year.
Context
- Stock-based compensation amounted to 9.0% of revenue in FY2025, up 1.0 pp from a year earlier.
- Stock-based compensation increased in 2 of the last 3 fiscal years.
What to watch
Whether quarterly stock-based compensation holds near $0 or moves back toward the trailing-twelve-month quarterly average of $1.65M.
Sources:Cash FlowText generated from reported figures; not investment advice.
Stock-Based Compensation history
USD · from the cash flow
- Latest · FY2025
- 17.83M USD
- Year-over-year change
- -10.4%
- 4-year CAGR
- +16.7%
| Period | Period end | Stock-Based Compensation | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 17.83M | -10.4% |
| FY2024 | 2024-12-31 | 19.89M | +59.1% |
| FY2023 | 2023-12-31 | 12.5M | +51.0% |
| FY2022 | 2022-12-31 | 8.28M | -14.0% |
| FY2021 | 2021-09-30 | 9.62M | — |
Stock-Based Compensation vs competitors
How SRTA compares with its peers on the latest reported figures
- Peers report in different currencies, so stock-based compensation is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of +21.9% is the 4th highest of 9, against a peer median of -8.2%.
- Stock-based compensation amounts to 2.6% of revenue for SRTA, versus a peer median of 0.9%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $41.39M USD | -31.5% | -14.8% | 9.3% | |
| LTM Mar 2026 | $40.05M USD | — | +91.2% | 45.5% | |
| LTM Mar 2026 | $13.68M USD | -3.7% | -8.0% | 1.0% | |
| LTM Mar 2026 | £10.35M GBP | — | -25.3% | — | |
| LTM Mar 2026 | $7.63M USD | -12.7% | +4.2% | 0.9% | |
SRTAStrata Critical Medical, Inc. | LTM Mar 2026 | $6.59M USD | +21.9% | +29.2% | 2.6% |
| LTM Mar 2026 | $5.9M USD | +23.5% | +25.5% | 0.7% | |
| LTM Mar 2026 | $4.96M USD | -71.4% | -18.1% | 2.7% | |
| LTM Mar 2026 | $2.59M USD | +143.2% | — | 0.7% | |
| LTM Feb 2026 | $1.93M USD | -51.5% | — | 0.5% | |
| LTM Apr 2026 | $1.03M USD | +121.1% | +27.2% | 0.1% | |
| Peer median (excluding SRTA) | — | -8.2% | -1.9% | 0.9% | |
Competitors are the stored peer set for SRTA. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Sep 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (40.05M) | (27.26M) | (56.08M) | (27.31M) | 41.35M |
| Depreciation & Amortization | 596K | 5.73M | 7.11M | 5.96M | 8.19M |
| Deferred Income Tax | (3.64M) | (772K) | (1.47M) | (255K) | 432K |
| Stock-Based Compensation | 9.62M | 8.28M | 12.5M | 19.89M | 17.83M |
| Change in Working Capital | (2.2M) | (17K) | (6.74M) | (3.01M) | (9.08M) |
| Accounts Receivables | (414K) | (5.35M) | (10.25M) | (998K) | (12.03M) |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Accounts Payables | 0 | 9.9M | 0 | 0 | 0 |
| Other Working Capital | (1.79M) | (4.57M) | 3.52M | (2.01M) | 2.95M |
| Other Non-Cash Items | 20.06M | (23.08M) | 12.32M | 2.2M | (107.63M) |
| Operating Cash Flow | (15.62M) | (37.13M) | (32.35M) | (2.52M) | (48.91M) |
| Capital Expenditures | (801K) | (730K) | (2.11M) | (32.99M) | (11.01M) |
| Acquisitions (Net) | (23.07M) | (48.1M) | (39K) | (2.23M) | (69.35M) |
| Purchases of Investments | (308.77M) | (228.21M) | (265.97M) | (143.26M) | (146.26M) |
| Sales of Investments | 11.3M | 356.38M | 285.07M | 177.45M | 296.36M |
| Other Investing Activities | (504K) | 0 | 138K | (2.11M) | (1.42M) |
| Investing Cash Flow | (321.34M) | 79.34M | 17.09M | (1.02M) | 69.75M |
| Debt Repayment | (1.17M) | 0 | 0 | 0 | 0 |
| Common Stock Issued | 119.63M | 87K | 0 | 0 | 193K |
| Common Stock Repurchased | 0 | 0 | 0 | (244K) | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 213.79M | (1.17M) | (76K) | (5.52M) | (9.11M) |
| Financing Cash Flow | 332.26M | (1.08M) | (76K) | (5.76M) | (8.91M) |
| Effect of Forex Changes | 10.97M | (4.29M) | (66K) | (80K) | (339K) |
| Net Change in Cash | (4.69M) | 36.84M | (15.4M) | (9.37M) | 11.59M |
| Free Cash Flow | (16.42M) | (37.86M) | (34.46M) | (35.51M) | (59.92M) |
Strata Critical Medical, Inc.
NASDAQ:SRTA
Intrinsic Alpha fair value
Locked
Current Price
$4.96
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.